VERU
Veru Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.64
−0.38%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +24.5%
- EBIT
- +43.8%
- EPS
- +69.0%
- Free cash flow
- +10.1%
- Operating cash flow
- +9.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +45.9%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +2.3%
- EBIT
- +33.0%
- Net income
- +39.9%
- EPS
- +44.6%
- Free cash flow
- -37.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026